PRECISION BIOSCIENCES INC
DTIL · Nasdaq · United States
Share price · DTIL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when DTIL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026-8.7%
- 5 Nov 2026+21.6%
- 4 Nov 2026+16.5%
- 28 Oct 2026+10.0%
Nothing announced by DTIL that day or the session before.
- 23 Sep 2026-11.5%
Nothing announced by DTIL that day or the session before.
- 22 Sep 2026+10.6%
Nothing announced by DTIL that day or the session before.
- 18 Aug 2026+11.2%
Nothing announced by DTIL that day or the session before.
- 7 Jul 2026+12.3%
Nothing announced by DTIL that day or the session before.
- 28 May 2026-8.8%
- 9 Apr 2026+10.4%
Nothing announced by DTIL that day or the session before.
Share of unusual movement by asset
For each asset, the share of DTIL's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Azercabtagene zapreleucelevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 3% |
| Other company news (earnings, financing, releases naming no asset) | — | 31% |
| Sessions with no dated event | — | 66% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CD19Cell therapy | Multiple SclerosisDiffuse Large B-Cell Lymphoma Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $13M | $108M+ $0.1M short-term inv. | $7.6M-$15M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $12M | $112M+ $1.5M short-term inv. | $33M-$13M operating cash flow | report ↗ |
| 2026-Q1 | $11M | $13M | $126M+ $1.8M short-term inv. | $18M-$12M operating cash flow | report ↗ |
| 2025-Q3 | <$0.1M | $13M | $71M+ $0 short-term inv. | $22M-$15M operating cash flow | report ↗ |
| 2025-Q2 | <$0.1M | $13M | $85M+ $0 short-term inv. | $24M-$20M operating cash flow | report ↗ |
| 2025-Q1 | <$0.1M | $14M | $100M | $21M-$19M operating cash flow | report ↗ |
| 2024-Q3 | $0.6M | $13M | $121M+ $2.5M short-term inv. | $16M-$5.9M operating cash flow | report ↗ |
| 2024-Q2 | $50M | $17M | $124M | —-$15M operating cash flow | report ↗ |
| 2024-Q1 | $18M | $13M | $138M | —-$19M operating cash flow | report ↗ |
| 2023-Q3 | $13M | $16M | $122M | $8.1M-$23M operating cash flow | report ↗ |
| 2023-Q2 | $20M | $22M | $138M | $12M-$21M operating cash flow | report ↗ |
| 2023-Q1 | $8.8M | $22M | $158M | $25M-$31M operating cash flow | report ↗ |
| 2022-Q3 | $7.4M | $20M | $212M | $24M$29M operating cash flow | report ↗ |
| 2022-Q2 | $3.8M | $23M | $184M | $31M-$24M operating cash flow | report ↗ |
| 2022-Q1 | $3.3M | $20M | $116M | $28M-$29M operating cash flow | report ↗ |
| 2021-Q3 | $24M | $26M | $160M | $11M-$24M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $34M | $54M | $137M+ $4.8M short-term inv. | $11M-$66M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $69M | $60M | $108M+ $0.4M short-term inv. | —-$58M operating cash flow | report ↗ |
| 2023-FY | $49M | $53M | $117M | $15M-$84M operating cash flow | report ↗ |
| 2022-FY | $25M | $84M | $190M | $28M-$46M operating cash flow | report ↗ |
| 2021-FY | $116M | $115M | $144M | $7.7M-$11M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($63K), 9 sales ($459K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | Scimeca Dario · Chief Legal Officer | Open-market sale | 2,821 | $9.75 | $28K | Form 4 |
| 2026-09-28 | Frankel Stanley · director | Open-market purchase | 1,000 | $6.00 | $6K | Form 4 |
| 2026-09-25 | Germano Geno J · director | Open-market purchase | 2,609 | $6.28 | $16K | Form 4 |
| 2026-09-25 | Brown Melinda · director | Open-market purchase | 1,135 | $6.27 | $7K | Form 4 |
| 2026-06-03 | Buehler Kevin · director | Award / grant (derivative) | 20,979 | — | — | Form 4 |
| 2026-06-03 | Pire Shari Lisa · director | Award / grant (derivative) | 20,979 | — | — | Form 4 |
| 2026-06-03 | Germano Geno J · director | Award / grant (derivative) | 20,979 | — | — | Form 4 |
| 2026-06-03 | Frankel Stanley · director | Award / grant (derivative) | 20,979 | — | — | Form 4 |